Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
주식 순위 #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
주가
$0.16328419
시가총액
$204.14K
변동 (1일)
4.35%
변동 (1년)
102.45%
국가
GB
거래 Fusion Antibodies plc (FAB)

카테고리

Fusion Antibodies plc (FAB)의 매출
Sep 2025 기준 매출 TTM: $2.15M
Fusion Antibodies plc의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $2.15M입니다. 2024년에 회사는 $1.43M의 수익을 올렸으며 이는 2023년의 $3.58M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Fusion Antibodies plc의 수익 기록 (2013 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$48.44B 2,257,473.65%
DK
$12.04B 560,997.32%
US
$14.34B 668,407.67%
US
$9.08B 423,215.14%
BE
$5.49B 255,843.08%
NL